NFG
TMBR

Nadler Financial Group’s Timber Pharmaceuticals, Inc. TMBR Stock Holding History

Nadler Financial Group’s Portfolio TMBR Stock Details TMBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-75
Closed -$27K – 90
2019
Q2 		$27K Buy
+75
New +$58.5K 0.01% 83

Other funds holding TMBR

Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Nadler Financial Group's TMBR Position: Q3 2019 in Review

Nadler Financial Group sold out of Timber Pharmaceuticals, Inc. (TMBR) in Q3 2019, closing a stake of 75 shares — an estimated $27K sold.

Nadler Financial Group first reported a position in TMBR in Q2 2019 and held it in 1 quarter. The position peaked at $27K in Q2 2019. 12 funds tracked by Wall St. Rank hold TMBR as of Q3 2019.

  • Nadler Financial Group reported no remaining Timber Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
  • Nadler Financial Group sold 75 Timber Pharmaceuticals, Inc. shares in Q3 2019, an estimated $27K.
  • Nadler Financial Group first reported a position in Timber Pharmaceuticals, Inc. in Q2 2019 and held it in 1 quarter.
  • Nadler Financial Group's Timber Pharmaceuticals, Inc. position peaked at $27K in Q2 2019.
  • 12 funds tracked by Wall St. Rank held Timber Pharmaceuticals, Inc. as of Q3 2019.

Based on Nadler Financial Group's 13F filing for Q3 2019, filed 3 Oct 2019.